Ignite Creation Date:
2024-05-06 @ 1:40 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01876212
Status:
COMPLETED
Last Update Posted:
2019-08-22
First Post:
2013-06-10
Brief Title:
Dendritic Cell Vaccines Dasatinib for Metastatic Melanoma
Sponsor:
Walter J Storkus
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen TBVA-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate and existing approaches including those involving immunotherapy with cytokines andor targeted strategies have resulted in disappointingly low rates of durable and complete responses Correcting immune dysfunction in advanced-stage melanoma patients using tyrosine-kinase inhibitor TKI such as dasatinib is proposed to relicense the patients immune system to respond optimally to specific immunization The integration of antigens expressed by tumor-associated blood vessel cells provides a means to selectively target the genetically-antigenically-heterogeneous population of tumor cells in the advanced-stage melanoma patient
This is a single-center prospective randomized Phase 2 trial evaluating the activity safety and immune effects of dasatinib given in combination with an autologous type-1 polarized Dendritic Cell αDC1 vaccine The current trial represents a randomized Phase 2 study to determine the activity and safety of intradermal id administration of αDC1s loaded with a mixture of six TBVA-derived peptides at the time of or immediately after an initial therapy cycle with the TKI dasatinib
Dasatinib will be administered at the standard dose and schedule recommended by the FDA 70 mg BID The autologous type-I DC vaccine will be administered either prior to or concomitant with the initiation of dasatinib administration All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting approximately every 12 hours at the same time each day
The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells with all the DCs being administered on days 1 and 15 of every cycle on an outpatient basis in the University of Pittsburgh Clinical and Translational Research Center UPCI-CTRC
Patients on Arm A will start dasatinib administration on cycle 2 day 1 week 5 while those patients in Arm B will start dasatinib administration on cycle 1 day 1 week 1
Men and women at least 18 years of age must be HLA-A2 and have histologically confirmed melanoma that is metastatic Stage IV or unresectable Stage IIIBC and for which standard curative or palliative measures do not exist or are no longer effective
Note The outcome measures and time frames previously described in the PRS protocol record have been revised and articulated in the results section to more accurately describe and represent the stated per-protocol investigations and endpoints quantitatively
This is a single-center prospective randomized Phase 2 trial evaluating the activity safety and immune effects of dasatinib given in combination with an autologous type-1 polarized Dendritic Cell αDC1 vaccine The current trial represents a randomized Phase 2 study to determine the activity and safety of intradermal id administration of αDC1s loaded with a mixture of six TBVA-derived peptides at the time of or immediately after an initial therapy cycle with the TKI dasatinib
Dasatinib will be administered at the standard dose and schedule recommended by the FDA 70 mg BID The autologous type-I DC vaccine will be administered either prior to or concomitant with the initiation of dasatinib administration All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting approximately every 12 hours at the same time each day
The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells with all the DCs being administered on days 1 and 15 of every cycle on an outpatient basis in the University of Pittsburgh Clinical and Translational Research Center UPCI-CTRC
Patients on Arm A will start dasatinib administration on cycle 2 day 1 week 5 while those patients in Arm B will start dasatinib administration on cycle 1 day 1 week 1
Men and women at least 18 years of age must be HLA-A2 and have histologically confirmed melanoma that is metastatic Stage IV or unresectable Stage IIIBC and for which standard curative or palliative measures do not exist or are no longer effective
Note The outcome measures and time frames previously described in the PRS protocol record have been revised and articulated in the results section to more accurately describe and represent the stated per-protocol investigations and endpoints quantitatively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UPCI 12-048 | OTHER | University of Pittsburgh Cancer Institute | httpsreporternihgovquickSearchR01CA169118 |
| R01CA169118 | NIH | None | None |